Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C

Bioconjugate Chemistry

Volumn 12, Issue 2, 2001, Pages 195-202

  Bailon, P ^a   Palleroni, A ^a   Schaffer, C A ^a   Spence, C L ^a   Fung, W J ^a   Porter, J E ^a   Ehrlich, G K ^a   Pan, W ^a   Xu, Z X ^a   Modi, M W ^a   Farid, A ^a   Berthold, W ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BODY FLUIDS; GLYCOPROTEINS; ISOMERS;

BRANCHED POLYETHYLENES; HEPATITIS C; IN-VITRO; IN-VIVO; LONG LASTING; PEGYLATED; POSITIONAL ISOMERS; RATIONAL DESIGN; SYNTHESISED; VIVO ANTI-TUMOR ACTIVITIES;

POLYETHYLENE GLYCOLS;

ANIMALIA; HEPATITIS C VIRUS; MUS MUSCULUS; VESICULAR STOMATITIS VIRUS;

EID: 0035086519     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc000082g     Document Type: Article

References (35)

1. The human interferons- From protein purification and sequence to cloning and expression in bacteria: Before, between and beyond
2. The interferons. Mechanisms of action and clinical applications
3. Alpha interferons: A clinical overview
4. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review
5. 13-Cis-retinoic acid and interferon α-a: Effective combination therapy for advanced squamous cell carcinoma of the skin
6. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
7. Clinical pharmacokinetics of interferons
8. Time course of interferon levels, anti-viral state, 2′,5′-oligoadenylate synthetase and side effects in healthy men
9. The clinical efficacy of poly(ethylene glycol)-modified proteins
10. The conjugation of proteins with poly(ethylene glycol) and other polymers; altering properties to enhance their therapeutic potential
11. Poly(ethylene glycol)-conjugated pharmaceutical proteins
12. Positional isomers of mono-pegylated interferon α-2a: Isolation, characterization, and biological activity
13. Strategies for the preparation and characterization of poly(ethylene glycol) (PEG) conjugated pharmaceutical proteins
14. Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers
15. A branched momomethoxypoly(ethylene glycol) for protein modification
16. Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins
17. PK/PD modeling approach to support clinical development of a long acting interferon (RO 25-3036) for the treatment of hepatitis C
18. Cleavage of structural protein during assembly of the head bacteriophage T4
19. Detection and molecular weight determination of poly(ethylene glycol)-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis
20. Accelerated clearance of poly(ethylene glycol)-modified proteins by anti-poly(ethylene glycol) IgM
21. Convenient assay for interferons
22. The detection of antibodies to recombinant interferon alfa-2a in human serum
23. Conformation of poly(ethylene oxide) in the solid state, melt and solution measured by Raman scattering
24. Definition of receptor binding domains in interferon α
25. The three-dimensional high resolutions structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution
26. Chemical modification of granulocyte colony stimulating factor by poly(ethylene glycol) increases its biological activity in vivo
27. Chemical modification of interleukin-2 by poly(ethylene glycol) increases its potency in the murine Meth A Sarcoma model
28. Chemical modification of natural human tumor necrosis factor-α with poly(ethylene glycol) increases its potency
29. A highly enhanced thrombopoietic activity by poly(ethylene glycol)-modified human interleukin-6
30. Modification of CD4 immunoadhesion IgG with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation